{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-058273","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.351981+00:00","generated_at":"2026-06-27T03:48:22.010434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track","bullets":["Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.","Full-year 2021 net loss $86.8M vs $41.7M in 2020; R&D spend $69.0M (up from $32.6M).","Cash, equivalents, and marketable securities $765.4M as of Dec 31, 2021.","FDA Fast Track for NUV-422 (high-grade gliomas); IND cleared for NUV-868 (solid tumors).","Expects Phase 1 safety data for NUV-422 in 2022; multiple pipeline milestones planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-058273","json":"https://secwatch.observer/filing/0001193125-22-058273.json","markdown":"https://secwatch.observer/filing/0001193125-22-058273.md","text":"https://secwatch.observer/filing/0001193125-22-058273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/0001193125-22-058273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/d261084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:48:22.010434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}